Nephrology and Dialysis Care: Market, Demand and Access Report

Summary

This report maps the nephrology and dialysis care market at global scope with United States detail, using only the latest available data in the source pack. End-stage kidney disease (ESKD) treated by dialysis or transplant is a growing burden in the United States. New cases and prevalent cases have risen sharply, while the adjusted rate of new cases fell over two decades ¹⁴. Market size estimates diverge. Market research publishers place the global dialysis equipment market at USD 107.1 billion ⁹ and the global dialysis market at USD 125.8 billion ¹¹. These are vendor-style estimates, and no authoritative figure was verified. Principal risks include racial and state-level disparities in ESKD ¹², per-treatment payment design ⁶⁸, and treatment interruptions from mortality and missed sessions ⁸. Major evidence gaps remain on workforce supply, waiting times, provider-sector quality and digital health adoption. The outlook points to continued demand growth, with forecasts treated as estimates ¹¹ and near-flat US treatment volumes expected by one operator ⁵. Stakeholders should obtain primary data on capacity, outcomes and access before making investment or policy decisions.

Key findings

1. 1

   United States ESKD counts are rising sharply

   Incident ESKD cases rose 41.8 percent, from 92,660 to 131,422, and prevalent cases rose 118.7 percent, from 358,247 to 783,594, between the baseline and the latest comparison in the CDC report. These are observed counts ⁴.

   Confidence: High
2. 2

   Adjusted incidence fell while case counts rose

   The US adjusted rate of new ESKD fell from 455 to 350 per million persons over two decades, while the number of new ESKD cases reached 132,020 per year in the latest data ¹. The pack does not explain the cause of this divergence, so population growth and ageing should be treated as possible factors, not established ones.

   Confidence: High
3. 3

   Disparities are large and documented

   ESKD prevalence among Black people remained more than four times that of White people in the latest data ¹. After Medicaid expansion, ESRD incidence rose in both expansion and non-expansion states, but more in non-expansion states, with an approximate gap of 10 cases per million population ².

   Confidence: Medium
4. 4

   Global market size has no verified consensus

   Market research estimates for the global dialysis market differ by publisher. The vendor-linked estimate is USD 125.8 billion, with a forecast of USD 181.2 billion and a 4.14 percent CAGR ¹¹. A separate equipment estimate is USD 107.1 billion ⁹. These should not be combined or treated as observed market values.

   Confidence: Qualitative
5. 5

   Operator revenue growth depends on revenue per treatment

   DaVita reported US dialysis revenue growth of 3.5 percent, driven by higher average patient services revenue per treatment ⁵. US treatments fell 1.4 percent over nine months, which the company attributed to higher mortality and missed treatments during a severe flu season ⁸.

   Confidence: Medium
6. 6

   Medicare bundled payment shapes provider economics

   Medicare pays for ESRD dialysis treatments under a single bundled payment ⁶. Phosphate binders were incorporated into the ESRD Prospective Payment System bundle, which partly explains higher revenue per treatment ⁸. These are company descriptions; the underlying CMS rule text was not retrieved.

   Confidence: Medium

1Industry definition and scope

This report covers nephrology and dialysis care for end-stage kidney disease. Several sources use the older term end-stage renal disease (ESRD) for the same population ³⁶. ESKD is treated mainly by dialysis or kidney transplantation ⁶. Dialysis includes in-center hemodialysis and home dialysis, including peritoneal dialysis ⁶¹⁰.

The source pack uses several overlapping counts, and they are not directly comparable. The NIDDK page describes people living with ESKD treated by transplant or dialysis ³. The International Society of Nephrology figure covers patients on regular dialysis ⁹. A separate estimate covers patients receiving renal replacement therapy ¹². Each count uses a different definition and date basis.

Geographic scope is global, with United States detail. The US figures come from official statistics and a peer-reviewed annual report ¹²⁴. Global figures come mainly from secondary market research and cite the International Society of Nephrology ⁹¹². The reporting period is the latest available data in the source pack, and forecasts are labelled as forecasts.

Segments covered are disease burden, market estimates, provider operations, home dialysis, payment and workforce where data exist. Clinical treatment decisions, individual patient care and legal or investment advice are outside scope.

2Market size, structure and value chain

Market size estimates vary by publisher and definition. One market research estimate puts the global dialysis equipment market at USD 107.1 billion ⁹. Another puts the global dialysis market at USD 125.8 billion, with a forecast of USD 181.2 billion and a 4.14 percent CAGR ¹¹. Both are vendor or market research estimates, not verified statistics. The source pack also notes lower estimates from other publishers, but these could not be attributed to a verified source and are not used here.

Regional structure is concentrated. One forecast places North America at 41.0 percent of the dialysis market ¹¹. A peritoneal dialysis analysis places North America at 33.1 percent of global peritoneal dialysis revenue ¹⁰. These figures use different market definitions and should not be compared directly.

The value chain runs from patient referral and nephrology care, to dialysis delivery in outpatient centers or at home, to equipment and consumables suppliers, and finally to payers. In the United States, Medicare pays for dialysis treatments under a single bundled payment ⁶. This is an interpretation of the payment flow, based on the operator's description.

Revenue models differ by setting. The US operator reports revenue growth driven by per-treatment revenue, with most services in outpatient hemodialysis ⁵⁶. Internationally, its footprint grew through acquisitions, with a net increase of 76 centers ⁵. Key stakeholders include patients, nephrology providers, dialysis operators, equipment suppliers, payers and regulators.

• Global dialysis equipment market (vendor estimate) 107.1USD billion Estimate Global, Latest available data [9]

Figures from the two market research publishers use different definitions (equipment versus total dialysis market). The writer has not reconciled them.

3Customers, demand and adoption

Demand is driven by the rising number of people with ESKD. In the United States, new ESKD cases reached 132,020 per year in the latest data ¹, and an incident case count of 131,422 was reported in the CDC series ⁴. Prevalent cases rose to 783,594 over the comparison period ⁴. Globally, the pack cites more than 3.5 million patients on regular dialysis ⁹ and roughly 2.6 million receiving renal replacement therapy ¹². These counts are not reconciled.

Demand is also rising earlier in the disease course. CKD stages 3 to 5 affect more than 10 percent of adults in over 40 countries, and incidence is reported as up 29 percent over the past decade, as cited by a market research summary ¹². This is secondary evidence and should be verified against primary sources.

Access differs by population. ESKD prevalence among Black people remained more than four times that of White people ¹. Medicaid expansion was associated with rising ESRD incidence in both expansion and non-expansion states, with the increase larger in non-expansion states ². The pack does not provide waiting-time or outcome data by group.

Home dialysis is a minority choice in the United States. Roughly 14.5 percent of US dialysis patients use home dialysis, according to a market analysis that does not state the year of the figure ¹⁰. Purchasing criteria for patients, referring clinicians and payers were not found in the pack. Patient preference data and adoption barriers are therefore treated as a gap.

• New ESKD cases in the United States 132,020people per year Observed United States, Latest available data [1]
• Prevalent ESKD cases in the United States 783,594prevalent cases Observed United States, Latest available data [4]

Counts from the CDC series and the US Renal Data System are close but not identical and may use different case definitions.

4Competitive landscape and key players

The source pack names one dialysis operator in detail: DaVita. As of the end of the first quarter of the latest available data, DaVita served about 282,000 patients at 3,173 outpatient dialysis centers in the United States and 13 other countries ⁷. Most of its services are outpatient hemodialysis ⁶. Its international footprint grew by a net 76 centers, mainly through acquisitions ⁵.

Comparison with other operators is not possible from the pack. Market share, concentration ratios and margins for other dialysis providers were not retrieved. Public, private non-profit and community provider comparisons on quality, outcomes and wait times were also not found.

Business models can be compared at a general level. Operator chains earn revenue per treatment under bundled payment, which rewards volume and cost control ⁵⁶. Equipment suppliers sell devices and consumables into this market ⁹¹¹. Market research publishers are not providers and their estimates reflect different definitions.

Competitive pressures visible in the pack include payment changes, which can shift revenue per treatment ⁸, and treatment interruptions from mortality and missed sessions ⁸. The writer's interpretation is that these pressures make operators more dependent on stable patient retention, but the pack contains no data to test this.

• Patients served by DaVita 282,000patients (approximate) Observed Global (United States and 13 other countries), End of first quarter, latest available data [7]

Only one operator is described in enough detail for comparison. Conclusions about concentration are therefore not supported by the pack.

5Technology, operations and workforce

Established practice includes in-center hemodialysis, home dialysis including peritoneal dialysis, and kidney transplantation ⁶¹⁰. These modalities are the current standard of delivery in the sources reviewed. Emerging or experimental approaches are not described in the pack.

Operational volume is measurable. DaVita's US dialysis treatments totalled 7,040,519 in the first quarter of the latest available data, averaging 91,793 per day ⁷. Treatments in the nine months to the end of the third quarter fell 1.4 percent ⁸. The operator attributed the fall to higher mortality and missed treatments during a severe flu season ⁸, which shows how seasonal illness affects operational throughput.

Payment design influences clinical product mix. Phosphate binders were incorporated into the ESRD Prospective Payment System bundle, which raised revenue per treatment ⁸. This is a clear example of payment rules shaping which therapies are funded within a bundle.

Digital health and remote monitoring adoption rates were not verified from primary sources. Workforce shortage data for nephrologists and dialysis technicians were not retrieved, so the workforce capacity analysis is limited to the observation that treatment volumes depend on staffed capacity. Productivity and skills data are not available in the pack.

• DaVita US dialysis treatments, first quarter 7,040,519treatments per quarter Observed United States, First quarter, latest available data [7]

6Regulation, standards, risk and sustainability

Jurisdiction for this section is the United States. Medicare payment for ESRD dialysis treatments is described as a single bundled payment ⁶. The underlying binding rule, the CMS ESRD Prospective Payment System rule, was not retrieved. Treat the bundled payment description as company reporting, not as verified regulatory text. Proposed rules and voluntary guidance were not found in the pack.

Device safety and quality standards, including ISO standards for dialysis devices, were not retrieved. Clinical quality and safety expectations for dialysis facilities are therefore not assessed. This report does not give engineering or clinical safety advice.

Privacy matters for patient-level data. This report uses only aggregate figures and does not present individual medical information. Equity data in the pack cover race, ethnicity and Medicaid expansion effects ¹², but not other social factors.

Operational risks visible in the pack include mortality and missed treatments during severe seasonal illness ⁸, payment design changes ⁸, and disparities in disease burden ¹². Environmental and sustainability factors were not covered by any source in the pack and are a gap.

Regulatory conclusions are limited to a company description of US Medicare payment and do not reflect the full rule set.

7Challenges, opportunities and case examples

The main challenges are rising disease burden ⁴, persistent racial disparities ¹, uneven state-level access effects ², and sensitivity of operator revenue to payment design and treatment interruptions ⁵⁸. Affordability and out-of-pocket costs by country were not retrieved beyond US Medicare statements, so cost pressure is only partly evidenced.

Opportunities include expanding home dialysis, where about 14.5 percent of US patients currently participate ¹⁰, and continued growth in demand for equipment and services, as forecast by market research ¹¹. The pack does not show whether home dialysis share is rising, so this opportunity is the writer's interpretation rather than an established trend.

Case example one is DaVita. Its US dialysis revenue grew 3.5 percent, driven by higher per-treatment revenue ⁵. In the same period, US treatments fell 1.4 percent over nine months ⁸. This shows that revenue growth can coexist with volume decline, but the pack does not give patient outcome data to explain the trade-off.

Case example two is a policy example rather than a company. Medicaid expansion states and non-expansion states experienced different changes in ESRD incidence ². Comparable company examples were limited to one operator in the pack, so no further provider comparison is made.

Table rows mix incidence, prevalence and home-dialysis measures from different publishers. They are presented side by side for orientation only.

8Outlook and strategic implications

In the near term, US demand is likely to remain high given the reported growth in cases ⁴. One operator expects approximately flat US treatment volumes in the period covered ⁵. This forecast is a company statement and is not an independent projection.

In the medium term, market research forecasts a 4.14 percent CAGR for the global dialysis market ¹¹. This is a vendor-linked forecast with an unverified base, so it should be used as a scenario input rather than a planning figure.

Three scenarios are plausible on the evidence. A base case of steady demand growth and stable per-treatment payment is consistent with the pack. An upside case depends on home dialysis expansion, which is not yet shown to be rising. A downside case involves outcome shocks, such as seasonal mortality ⁸, or payment changes, which are already visible in the pack ⁸. The likelihood of each scenario is a judgment, not a measured result.

Practical implications differ by stakeholder. Providers need local data on capacity, outcomes and access. Suppliers should validate market estimates before using them in planning. Payers and policymakers need workforce, waiting-time and affordability data, which the pack lacks. Investors should treat vendor forecasts with caution, as the market estimates conflict.

9Conclusion

The clearest evidence in the pack is that US ESKD counts and prevalence are rising, while disparities remain large. Global market size is not reliably measured, and the workforce, waiting-time and provider-quality evidence needed for a full assessment is missing. The most defensible takeaways are the observed burden trends, the documented disparities and the payment-driven economics of dialysis operators.

How this was built

Sources

1. 1

   Annual Data Report - Incidence and Prevalence (US Renal Data System)

   United States Renal Data System (NIDDK, NIH) Official statistics

   usrds-adr.niddk.nih.gov
2. 2

   USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States

   United States Renal Data System; American Journal of Kidney Diseases Peer-reviewed

   ajkd.org
3. 3

   Kidney Disease Statistics for the United States

   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, NIH) Official statistics

   niddk.nih.gov
4. 4

   Reported Cases of End-Stage Kidney Disease, United States

   Centers for Disease Control and Prevention (MMWR) Official statistics

   cdc.gov
5. 5

   DaVita Inc. Form 10-K for latest fiscal year

   DaVita Inc. (filed with US Securities and Exchange Commission) Company report

   sec.gov
6. 6

   DaVita Annual Report, Business Description

   DaVita Inc. Company report

   investors.davita.com
7. 7

   DaVita Inc. 1st Quarter Results

   DaVita Inc. Company report

   investors.davita.com
8. 8

   DaVita 10-Q for quarter ended September 30

   DaVita Inc. Company report

   sec.gov
9. 9

   Dialysis Equipment Market Size, Share and Growth (cites International Society of Nephrology)

   SNS Insider (market research) Market research

   snsinsider.com
10. 10

    Peritoneal Dialysis Market Analysis and Forecast

    Global Market Insights (market research) Market research

    gminsights.com
11. 11

    Dialysis Market Size, Share, Growth and Trends Report

    IMARC Group (market research) Market research

    imarcgroup.com
12. 12

    Global Kidney Health Atlas (cited within market research summary)

    International Society of Nephrology (as cited by Market Research Future) Market research

    marketresearchfuture.com